{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T18:16:22Z","timestamp":1782324982163,"version":"3.54.5"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Japanese Osteoporosis Society"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To investigate the effectiveness of denosumab (DMAb), teriparatide (TPTD) and romosozumab (ROMO) in patients with glucocorticoid-induced osteoporosis (GIOP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>This multicenter, retrospective cohort study employed propensity score matching to select 42 patients per treatment group [92.1% female, mean age 73.5\u2009years, 35.7% osteoporosis treatment naive, oral glucocorticoids (prednisolone equivalent) 5.4\u2009mg\/day, baseline bone mineral density (BMD) T-scores: lumbar spine (LS) \u22122.5]. Bone turnover markers (BTMs) and BMD were assessed over 12\u2009months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>DMAb suppressed BTM levels, whereas TPTD increased them. ROMO showed a dual effect, with increased and decreased levels of formation and resorption markers, respectively. At 12\u2009months, LS BMD increases were greater with ROMO (9.5%) and tended to be higher with TPTD (8.4%) compared with DMAb (4.4%) (P = 0.008 for ROMO vs DMAb). At 6\u2009months, total hip BMD increased with DMAb (2.6%) and ROMO (1.8%) but decreased with TPTD (\u22120.6%; P = 0.01 for DMAb vs TPTD; P = 0.042 for ROMO vs TPTD); no significant differences were observed at 12\u2009months (3.2%, 2.6%, 2.2%, respectively). DMAb showed significant increases in femoral neck BMD at 6 (2.2%) and 12 (3.0%) months from baseline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>BTM levels reflected expected pharmacological actions of each drug. ROMO showed greater LS BMD gains than DMAb, while TPTD demonstrated a similar response, whereas DMAb may provide earlier benefits at cortical-rich sites. These findings underscore the importance of site-specific, individualized treatment strategies for GIOP.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keag082","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T12:40:34Z","timestamp":1770295234000},"source":"Crossref","is-referenced-by-count":2,"title":["Effectiveness of denosumab, teriparatide and romosozumab for glucocorticoid-induced osteoporosis: a propensity score-matched cohort study"],"prefix":"10.1093","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2265-6724","authenticated-orcid":false,"given":"Toshitaka","family":"Yukishima","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Internal Medicine III, Hamamatsu University School of Medicine , Hamamatsu, Shizuoka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Kobayakawa","sequence":"additional","affiliation":[{"name":"Kobayakawa Orthopaedics and Rheumatologic Clinic , Fukuroi, Shizuoka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0422-8139","authenticated-orcid":false,"given":"Yuji","family":"Hirano","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Toyohashi Municipal Hospital , Toyohashi, Aichi,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhide","family":"Kanayama","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery and Rheumatology, Toyota Kosei Hospital , Toyota, Aichi,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2001-0674","authenticated-orcid":false,"given":"Rui","family":"Niimi","sequence":"additional","affiliation":[{"name":"Niimi Orthopaedic Clinic , Kuwana, Mie,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5741-5969","authenticated-orcid":false,"given":"Yuki","family":"Etani","sequence":"additional","affiliation":[{"name":"Department of Sports Medical Biomechanics, The University of Osaka Graduate School of Medicine Faculty of Medicine , Suita, Osaka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9938-6780","authenticated-orcid":false,"given":"Takaaki","family":"Noguchi","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, The University of Osaka Graduate School of Medicine Faculty of Medicine , Suita, Osaka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3496-3956","authenticated-orcid":false,"given":"Kumiko","family":"Shimoyama","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Internal Medicine III, Hamamatsu University School of Medicine , Hamamatsu, Shizuoka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6792-8458","authenticated-orcid":false,"given":"Yuichiro","family":"Maekawa","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine , Hamamatsu, Shizuoka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4086-4984","authenticated-orcid":false,"given":"Ken","family":"Nakata","sequence":"additional","affiliation":[{"name":"Department of Health and Sport Sciences, The University of Osaka Graduate School of Medicine Faculty of Medicine , Suita, Osaka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5107-8209","authenticated-orcid":false,"given":"Seiji","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, The University of Osaka Graduate School of Medicine Faculty of Medicine , Suita, Osaka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2426-1024","authenticated-orcid":false,"given":"Kosuke","family":"Ebina","sequence":"additional","affiliation":[{"name":"Department of Sports Medical Biomechanics, The University of Osaka Graduate School of Medicine Faculty of Medicine , Suita, Osaka,","place":["Japan"]},{"name":"Department of Orthopaedic Surgery, The University of Osaka Graduate School of Medicine Faculty of Medicine , Suita, Osaka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"2026031219464945600_keag082-B1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s12020-018-1588-2","article-title":"Glucocorticoid-induced osteoporosis: an update","volume":"61","author":"Compston","year":"2018","journal-title":"Endocrine"},{"key":"2026031219464945600_keag082-B2","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1172\/JCI2799","article-title":"Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone","volume":"102","author":"Weinstein","year":"1998","journal-title":"J Clin Invest"},{"key":"2026031219464945600_keag082-B3","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1056\/NEJMcp1800214","article-title":"Glucocorticoid-induced osteoporosis","volume":"379","author":"Buckley","year":"2018","journal-title":"N Engl J Med"},{"key":"2026031219464945600_keag082-B4","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMcp1012926","article-title":"Clinical practice. Glucocorticoid-induced bone disease","volume":"365","author":"Weinstein","year":"2011","journal-title":"N Engl J Med"},{"key":"2026031219464945600_keag082-B5","doi-asserted-by":"crossref","first-page":"e179963","DOI":"10.1172\/jci.insight.179963","article-title":"The pivotal role of the Hes1\/Piezo1 pathway in the pathophysiology of glucocorticoid-induced osteoporosis","volume":"9","author":"Ochiai","year":"2024","journal-title":"JCI Insight"},{"key":"2026031219464945600_keag082-B6","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s00198-007-0394-0","article-title":"Glucocorticoid-induced osteoporosis: pathophysiology and therapy","volume":"18","author":"Canalis","year":"2007","journal-title":"Osteoporos Int"},{"key":"2026031219464945600_keag082-B7","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1002\/art.42529","article-title":"Bone loss in inflammatory rheumatic musculoskeletal disease patients treated with low-dose glucocorticoids and prevention by anti-osteoporosis medications","volume":"75","author":"Adami","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2026031219464945600_keag082-B8","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00774-024-01502-w","article-title":"The 2023 Guidelines for the management and treatment of glucocorticoid-induced osteoporosis","volume":"42","author":"Tanaka","year":"2024","journal-title":"J Bone Miner Metab"},{"key":"2026031219464945600_keag082-B9","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1002\/art.42646","article-title":"2022 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"75","author":"Humphrey","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2026031219464945600_keag082-B10","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/nrendo.2015.71","article-title":"Short-term and long-term effects of osteoporosis therapies","volume":"11","author":"Reid","year":"2015","journal-title":"Nat Rev Endocrinol"},{"key":"2026031219464945600_keag082-B11","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/art.43179","article-title":"Expert perspective: how, when, and why to potentially stop antiresorptive drugs in osteoporosis","volume":"77","author":"Adami","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"2026031219464945600_keag082-B12","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1007\/s00198-011-1804-x","article-title":"Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw","volume":"22","author":"Compston","year":"2011","journal-title":"Osteoporos Int"},{"key":"2026031219464945600_keag082-B13","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/art.40874","article-title":"Denosumab versus risedronate in glucocorticoid-induced osteoporosis: final results of a twenty-four-month randomized, double-blind, double-dummy trial","volume":"71","author":"Saag","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2026031219464945600_keag082-B14","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1002\/art.24879","article-title":"Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial","volume":"60","author":"Saag","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2026031219464945600_keag082-B15","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/mr\/roac014","article-title":"Comparable efficacy of denosumab and romosozumab in patients with rheumatoid arthritis receiving glucocorticoid administration","volume":"33","author":"Kobayakawa","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2026031219464945600_keag082-B16","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00198-024-07336-6","article-title":"Effect of romosozumab on bone mineral density and trabecular bone score in premenopausal women with low bone mass","volume":"36","author":"Lee","year":"2025","journal-title":"Osteoporos Int"},{"key":"2026031219464945600_keag082-B17","doi-asserted-by":"crossref","first-page":"e2778","DOI":"10.1210\/clinem\/dgae810","article-title":"Comparison of efficacy of romosozumab with denosumab and risedronate in patients newly initiating glucocorticoid therapy","volume":"110","author":"Kawazoe","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2026031219464945600_keag082-B18","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1007\/s00198-012-2093-8","article-title":"Treatment failure in osteoporosis","volume":"23","author":"Diez-Perez","year":"2012","journal-title":"Osteoporos Int"},{"key":"2026031219464945600_keag082-B19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11657-012-0109-9","article-title":"Japanese 2011 guidelines for prevention and treatment of osteoporosis\u2014executive summary","volume":"7","author":"Orimo","year":"2012","journal-title":"Arch Osteoporos"},{"key":"2026031219464945600_keag082-B20","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","article-title":"Vertebral fracture assessment using a semiquantitative technique","volume":"8","author":"Genant","year":"1993","journal-title":"J Bone Miner Res"},{"key":"2026031219464945600_keag082-B21","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00198-025-07386-4","article-title":"Impact of switching from bisphosphonates to denosumab, teriparatide, or romosozumab in patients with postmenopausal osteoporosis: a case-control study","volume":"36","author":"Yukishima","year":"2025","journal-title":"Osteoporos Int"},{"key":"2026031219464945600_keag082-B22","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jocd.2016.03.003","article-title":"Best practices for dual-energy X-ray absorptiometry measurement and reporting: international society for clinical densitometry guidance","volume":"19","author":"Lewiecki","year":"2016","journal-title":"J Clin Densitom"},{"key":"2026031219464945600_keag082-B23","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s00198-018-4492-y","article-title":"Impact of switching oral bisphosphonates to denosumab or daily teriparatide on the progression of radiographic joint destruction in patients with biologic-naive rheumatoid arthritis","volume":"29","author":"Ebina","year":"2018","journal-title":"Osteoporos Int"},{"key":"2026031219464945600_keag082-B24","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00198-024-07019-2","article-title":"An investigation of the differential therapeutic effects of romosozumab on postmenopausal osteoporosis patients with or without rheumatoid arthritis complications: a case-control study","volume":"35","author":"Ebina","year":"2024","journal-title":"Osteoporos Int"},{"key":"2026031219464945600_keag082-B25","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S0895-4356(96)00236-3","article-title":"A simulation study of the number of events per variable in logistic regression analysis","volume":"49","author":"Peduzzi","year":"1996","journal-title":"J Clin Epidemiol"},{"key":"2026031219464945600_keag082-B26","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.jclinepi.2013.01.013","article-title":"Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research","volume":"66","author":"Stuart","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"2026031219464945600_keag082-B27","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/jbmr\/zjaf110","article-title":"Increase in serum DKK1 levels attenuates the anabolic response to romosozumab in postmenopausal osteoporosis","volume":"41","author":"Adami","year":"2026","journal-title":"J Bone Miner Res"},{"key":"2026031219464945600_keag082-B28","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1172\/JCI6610","article-title":"Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone","volume":"104","author":"Jilka","year":"1999","journal-title":"J Clin Invest"},{"key":"2026031219464945600_keag082-B29","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.bone.2007.03.017","article-title":"Molecular and cellular mechanisms of the anabolic effect of intermittent PTH","volume":"40","author":"Jilka","year":"2007","journal-title":"Bone"},{"key":"2026031219464945600_keag082-B30","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bone.2016.10.007","article-title":"Role and mechanism of action of sclerostin in bone","volume":"96","author":"Delgado-Calle","year":"2017","journal-title":"Bone"},{"key":"2026031219464945600_keag082-B31","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"357","author":"Saag","year":"2007","journal-title":"N Engl J Med"},{"key":"2026031219464945600_keag082-B32","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N Engl J Med"},{"key":"2026031219464945600_keag082-B33","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1002\/jbmr.2480","article-title":"Sustained modeling-based bone formation during adulthood in cynomolgus monkeys may contribute to continuous BMD gains with denosumab","volume":"30","author":"Ominsky","year":"2015","journal-title":"J Bone Miner Res"},{"key":"2026031219464945600_keag082-B34","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/jbmr.2152","article-title":"Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody","volume":"29","author":"Ominsky","year":"2014","journal-title":"J Bone Miner Res"},{"key":"2026031219464945600_keag082-B35","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1359\/jbmr.2001.16.1.157","article-title":"Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys","volume":"16","author":"Burr","year":"2001","journal-title":"J Bone Miner Res"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keag082\/66865454\/keag082.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/3\/keag082\/66865454\/keag082.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/3\/keag082\/66865454\/keag082.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T23:46:58Z","timestamp":1773359218000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/doi\/10.1093\/rheumatology\/keag082\/8475409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,5]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keag082","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,2,12]]},"article-number":"keag082"}}